in situ – Talk Bio

J&J’s Inlexzo Bladder Cancer Therapy Wins ‘Practice-Changing’ FDA Approval

10 hours ago talkbio0Tagged Approved, BCG-Unresponsive, Carcinoma, Drug Delivery Systems, gemcitabine intravesical system, in situ, Inlexzo, Johnson & Johnson, Malignant neoplasm of urinary bladder, New, Non-Muscle Invasive Bladder Neoplasms, SunRISe-1 trial, United States Food and Drug Administration

Inlexzo; FDA approval; bladder cancer; Johnson & Johnson; gemcitabine intravesical system; BCG-unresponsive; non-muscle invasive bladder cancer; SunRISe-1 trial; novel drug delivery; carcinoma in situ

As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense

5 months ago talkbio0Tagged Anktiva, BCG-Unresponsive, bladder-sparing treatment, Carcinoma in Situ, gemcitabine releasing system, ImmunityBio, in situ, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, TAR 200

TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment

Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding

8 months ago talkbio0Tagged CAR-T, Clearance, Hematologic Neoplasms, in situ, Series, UB-VV111, Umoja Biopharma, United States Food and Drug Administration

Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding